Fubotv earnings beat by $0.10, revenue topped estimates
Investing.com - Leerink Partners has reduced its price target on Certara Inc . (NASDAQ:CERT) to $11.50 from $13.00 while maintaining an Outperform rating on the stock. The company’s shares currently trade at $11.13, with analyst targets ranging from $13 to $18. According to InvestingPro analysis, the stock appears slightly undervalued based on its Fair Value metrics.
The price target adjustment represents an approximately 11.5% decrease from the previous target set by the research firm for the biosimulation software company.
Despite the lower price target, Leerink Partners has kept its Outperform rating intact, suggesting the firm maintains a positive long-term outlook on Certara’s business prospects.
Certara provides biosimulation software and technology-enabled services that transform drug discovery and development for pharmaceutical and biotechnology companies.
The price target reduction comes as part of Leerink Partners’ ongoing evaluation of Certara’s valuation metrics and growth trajectory in the current market environment.
In other recent news, Certara Inc. announced its second-quarter 2025 earnings, showing a mixed financial performance. The company’s earnings per share (EPS) did not meet analysts’ expectations. However, Certara’s revenue slightly surpassed forecasts, indicating some positive momentum in its financial results. These developments have drawn attention from investors as they assess the company’s financial health. Despite the revenue beat, the market’s reaction was negative, reflecting concerns over the missed EPS target. The company’s latest earnings report has become a focal point for analysts and investors alike. These recent developments highlight the ongoing scrutiny of Certara’s financial performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.